Status:
RECRUITING
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
Lead Sponsor:
Acute Leukemia French Association
Conditions:
Acute Myeloid Leukemia (AML)
Eligibility:
All Genders
18+ years
Brief Summary
During the last fifteen years, the landscape of AML diagnosis and therapeutical options has markedly evolved. Refined genetic and prognostic characterizations, together with new drug approvals and new...
Detailed Description
During the last fifteen years, the landscape of AML diagnosis and therapeutical options has markedly evolved. Refined genetic and prognostic characterizations, together with new drug approvals and new...
Eligibility Criteria
Inclusion
- Patient aged 18 years old or more
- Patient with newly diagnosed previously untreated de novo, secondary or therapy-related AML
- Patients with R/R de novo, secondary or therapy-related AML
- Patient with Health insurance
Exclusion
- Acute promyelocytic leukemia
- AML which is not morphologically proven (patients with granulocytic sarcoma may be included)
- For newly diagnosed AML: previous treatment of leukemia apart from hydroxyurea. Previous anti leukemia treatments are allowed if they were administered before the diagnosis of AML to treat a MDS, MPN, MPN/MDS or CML
- Patient weighting less than 50 kgs
- Opposition of the patient to participate to this non-interventional study
- More specific eligibility criteria might be requested to enter some study modules
Key Trial Info
Start Date :
April 14 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2046
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT04777916
Start Date
April 14 2022
End Date
April 1 2046
Last Update
October 3 2025
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Amiens
Amiens, France
2
Centre Hospitalier Victor Dupouy
Argenteuil, France
3
AP-HP-GHU - Hôpital AVICENNE
Bobigny, France
4
CHU de la cote de Nacre
Caen, France